StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com has begun coverage of the stock InspireMD (NYSE:NSPR – Free Report) in a research note published on Thursday. The firm issued a sell rating on the stock.

InspireMD stock performance

Shares of NSPR stock opened at $2.85 on Thursday. The stock has a market cap of $71.05 million, a PE ratio of -3.75 and a beta of 0.96. The company’s fifty day moving average is $2.67 and its 200 day moving average is $2.50. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.85.

InspireMD (NYSE:NSPR – Get Your Free Report ) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The company had revenue of $1.74 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 350.35% and a negative return on equity of 55.12%. During the same period in the previous year, the company earned ($0.24) earnings per share. As a group, research analysts forecast that InspireMD will post -0.82 earnings per share for the current year.

Hedge funds influence InspireMD

Large investors have recently made changes to their positions in the company. McKinley Carter Wealth Services Inc. purchased a new stake in InspireMD in the fourth quarter valued at about $28,000. Rosalind Advisors Inc. boosted its position in shares of InspireMD by 266.4% in the second quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock valued at $6,272,000 after purchasing an additional 1,827,579 shares during the period. Finally, Mesirow Financial Investment Management Inc. bought a new position in shares of InspireMD in the first quarter valued at approximately $71,000. 44.78% of the shares are held by hedge funds and other institutional investors.

InspireMD Company Profile

(Get a free report)

InspireMD, Inc, a medical device company, is focused on developing and commercializing the MicroNet stent platform technology for the treatment of vascular and coronary artery disease in Europe, Latin America, the Middle East and Asia Pacific. The company offers the CGuard Carotid Embolism Prevention System (EPS) for use in carotid artery applications; CGuard Prime Stent System, a self-expanding mesh-covered carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute cerebrovascular accident with tandem lesions.

Further reading

Get news and reviews for InspireMD Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for InspireMD and related companies with MarketBeat.com’s FREE daily email newsletter.